Page last updated: 2024-12-06

guanoxabenz

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID9567831
CHEMBL ID461343
CHEBI ID135006
MeSH IDM0092289

Synonyms (22)

Synonym
guanoxabenz
guanoxabenz (usan/inn)
24047-25-4
D04398
CHEBI:135006
CHEMBL461343
p9hik5v7wk ,
hydrazinecarboximidamide, 2-((2,6-dichlorophenyl)methylene)-n-hydroxy-
1-((2,6-dichlorobenzylidene)amino)-3-hydroxyguanidine
guanoxabenz [usan:inn]
unii-p9hik5v7wk
guanoxabenz [mi]
guanoxabenz [who-dd]
guanoxabenz [inn]
1-[(2,6-dichlorobenzylidene)amino]-3-hydroxyguanidine
guanoxabenz [usan]
hydroxyguanabenz
HY-U00123
CS-7160
DB13410
2-[(e)-(2,6-dichlorophenyl)methylideneamino]-1-hydroxyguanidine
AKOS040733338

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" These substances are amidoxime/N-hydroxyguanidine prodrugs, leading to improved bioavailability compared to the active amidines/guanidines."( The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs.
Bittner, F; Clement, B; Gruenewald, S; Hungeling, H; Kanzow, S; Kotthaus, J; Mendel, RR; Schwering, U; Wahl, B, 2008
)
0.35

Dosage Studied

ExcerptRelevanceReference
") produced about a 10 fold rightward shift of the dose-response curve for guanoxabenz."( alpha 2-Adrenoceptor agonists induced mydriasis in the rat by an action within the central nervous system.
Berridge, TL; Gadie, B; Roach, AG; Tulloch, IF, 1983
)
0.27
" In contrast, the dose-response curves to tiamenidine and clonidine were flatter and bell-shaped with maxima of 30 and 60 min, respectively."( Sleeping times evoked by alpha adrenoceptor agonists in two-day-old chicks: an experimental model to evaluate full and partial agonists at central alpha-2 adrenoceptors.
Cavero, I; Doxey, JC; Roach, AG; Strachan, DA, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID409214Specific activity at molybdenum cofactor/metal-free precursor molybopterin bound human recombinant mARC1 expressed in Escherichia coli TP1000 assessed as reduction to guanabenz in complete reconstituted system containing microsomal cyt b5, NADH and micros2008Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24
The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs.
AID1653808Substrate activity at human mARC2 expressed in Escherichia coli assessed as turnover rates at 500 uM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by LC-MS analysis based assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID1653798Substrate activity at human mARC2 expressed in Escherichia coli assessed as turnover rates at 500 uM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID1653803Substrate activity at human mARC1 expressed in Escherichia coli assessed as turnover rates at 500 uM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by LC-MS analysis based assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID1653793Substrate activity at human mARC1 expressed in Escherichia coli assessed as turnover rates at 500 uM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (31.58)18.7374
1990's10 (52.63)18.2507
2000's2 (10.53)29.6817
2010's0 (0.00)24.3611
2020's1 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.76%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]